Literature DB >> 20409403

Increase in pneumococcus macrolide resistance, USA.

Lauri A Hicks, Dominique L Monnet, Rebecca M Roberts.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20409403      PMCID: PMC2953996          DOI: 10.3201/eid1605.091424

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Jenkins and Farrell reported an increase in the proportion of macrolide-resistant Streptococcus pneumoniae isolates in the United States (). They mentioned increased use and inappropriate prescription of macrolides as potential explanations for the increase in macrolide resistance and expressed doubts, stating “which (if any) of these factors might explain the trends here are not clear.” Although the spread of antimicrobial drug resistance is a complex issue with many contributing factors, we believe that the role of macrolide use should not be understated. Several studies in Europe have provided evidence for a relationship between macrolide use and resistance. Macrolide exposure leads to emergence of macrolide resistance on the individual level, and countries in Europe with higher outpatient sales of macrolides have more macrolide-resistant pneumococci (). Outpatient antimicrobial drug use in the United States has decreased since 1995–1996, especially among children. However, use of azithromycin increased in children, and use of macrolides increased in older patients from 1995–1996 through 2005–2006 (). In this context, it would be surprising that after this increase, pneumococci would show different characteristics in the United States than in Europe. A 2001 study showed that increased macrolide use in the United States during 1995–1999 coincided with a doubling of the proportion of macrolide-resistant pneumococci (), and further increases in macrolide use since 1999 () have contributed to the increase in macrolide-resistant pneumococci. Decreased macrolide use has led to a decrease in macrolide-resistant pneumococci. A yearly seasonal reduction in antimicrobial drug prescribing in Israel was associated with a decrease in the proportion of antimicrobial drug–resistant pneumococci that caused acute otitis media (). With the introduction of expanded-valent pneumococcal conjugate vaccines, there is promise that drug-resistant pneumococcal disease can be reduced. Nevertheless, judicious use of antimicrobial drugs and a decrease in unnecessary prescriptions, as promoted by the Get Smart: Know When Antibiotics Work (www.cdc.gov/getsmart) campaign, are essential to limiting selection and spread of antimicrobial drug resistance.
  5 in total

1.  Macrolide resistance among invasive Streptococcus pneumoniae isolates.

Authors:  T B Hyde; K Gay; D S Stephens; D J Vugia; M Pass; S Johnson; N L Barrett; W Schaffner; P R Cieslak; P S Maupin; E R Zell; J H Jorgensen; R R Facklam; C G Whitney
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

2.  Outpatient antibiotic use in Europe and association with resistance: a cross-national database study.

Authors:  Herman Goossens; Matus Ferech; Robert Vander Stichele; Monique Elseviers
Journal:  Lancet       Date:  2005 Feb 12-18       Impact factor: 79.321

3.  Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings.

Authors:  Carlos G Grijalva; J Pekka Nuorti; Marie R Griffin
Journal:  JAMA       Date:  2009-08-19       Impact factor: 56.272

4.  Seasonality of antibiotic-resistant streptococcus pneumoniae that causes acute otitis media: a clue for an antibiotic-restriction policy?

Authors:  Ron Dagan; Galia Barkai; Noga Givon-Lavi; Amir Z Sharf; Daniel Vardy; Ted Cohen; Marc Lipsitch; David Greenberg
Journal:  J Infect Dis       Date:  2008-04-15       Impact factor: 5.226

5.  Increase in pneumococcus macrolide resistance, United States.

Authors:  Stephen G Jenkins; David J Farrell
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

  5 in total
  2 in total

1.  Microbiological airway colonization in COPD patients with severe emphysema undergoing endoscopic lung volume reduction.

Authors:  Franziska C Trudzinski; Frederik Seiler; Heinrike Wilkens; Carlos Metz; Annegret Kamp; Robert Bals; Barbara Gärtner; Philipp M Lepper; Sören L Becker
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-12-19

2.  Antibiotic resistance profiles and multidrug resistance patterns of Streptococcus pneumoniae in pediatrics: A multicenter retrospective study in mainland China.

Authors:  Cai-Yun Wang; Ying-Hu Chen; Chao Fang; Ming-Ming Zhou; Hong-Mei Xu; Chun-Mei Jing; Hui-Ling Deng; Hui-Jun Cai; Kai Jia; Shu-Zhen Han; Hui Yu; Ai-Min Wang; Dan-Dan Yin; Chuan-Qing Wang; Wei Wang; Wei-Chun Huang; Ji-Kui Deng; Rui-Zhen Zhao; Yi-Ping Chen; Ji-Hong Yang; Chun Wang; Yan-Ran Che; Xiu-Zhen Nie; Shi-Fu Wang; Jian-Hua Hao; Cong-Hui Zhang
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.